STOCK TITAN

Cellectar Biosciences Inc - CLRB STOCK NEWS

Welcome to our dedicated news page for Cellectar Biosciences (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellectar Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellectar Biosciences's position in the market.

Rhea-AI Summary
Cellectar Biosciences announces significant advancements to its global intellectual property portfolio, securing four patents across Europe, Australia, and Canada. The patents enhance the use of iopofosine I 131 for treating various cancers and underserved pediatric diseases, identify and isolate circulating tumor cells, and enable targeted anticancer agents. The expanded protection supplements the existing patent portfolio and supports the company's mission to transform cancer care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
Cellectar Biosciences receives PRIME designation from EMA for iopofosine I 131 in WM patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
Rhea-AI Summary
Cellectar Biosciences closes private placement with gross proceeds of $102.9 million, including $24.5 million received at closing. Lead asset iopofosine receives Fast Track Designation from FDA. Company expects top-line data from pivotal trial in H2 2023 and aims for 2024 product launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
Rhea-AI Summary
Cellectar Biosciences announces private placement financing of up to $102.9 million led by Rosalind Advisors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.53%
Tags
conferences
Cellectar Biosciences Inc

Nasdaq:CLRB

CLRB Rankings

CLRB Stock Data

44.67M
9.20M
3.78%
32.28%
16.34%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Florham Park

About CLRB

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p